Signify share repurchase period update
Eindhoven, the Netherlands - Signify ( Euronext: LIGHT ) , the world leader in lighting, today announced that it has repurchased 49,249 shares in the period June 9 to June 13, 2025. The shares were repurchased at an average price of EUR 22.13 per share and an aggregate amount of EUR 1.1 million.
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® ( berotralstat ) Across all Ages at EAACI
-Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety ...
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - Axsome Therapeutics ( NASDAQ:AXSM )
NEW YORK, June 16, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. AXSM, a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, is proud to recognize Migraine and Headache Awareness Month alongside the Association of Migraine Disorders.
Fury Finalizes Drill Targeting at its Newly Acquired Sakami Gold Project - Fury Gold Mines ( AMEX:FURY )
TORONTO, June 16, 2025 ( GLOBE NEWSWIRE ) -- Fury Gold Mines Limited FURY ( "Fury" or the "Company" ) is pleased to announce that is has finalized a number of drill targets at the Sakami gold project located in the Eeyou Istchee Territory in the James Bay region of Northern Quebec ( Figure 1 ) .
The US-China rivalry is reshaping global supply chains - who benefits most?
Supply chain competition between China and the United States is set to intensify over the next five years, with eight developing countries - including four in the Association of Southeast Asian Nations (Asean) - poised to benefit from the relocation of manufacturing from China, according to a ...
China's robotics market set to double in four years: Morgan Stanley
China's robotics market is set to grow at an annual rate of 23 per cent to US$108 billion by 2028 from US$47 billion in 2024, solidifying the country's dominant position in the fast-developing sector, according to a research note published by Morgan Stanley on Monday.
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease
MALVERN, Pa., June 16, 2025 ( GLOBE NEWSWIRE ) -- Ocugen, Inc. ( Ocugen or the Company ) ( NASDAQ: OCGN ) , a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the Investigational New Drug ( IND ...
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen ( NASDAQ:OCGN )
MALVERN, Pa., June 16, 2025 ( GLOBE NEWSWIRE ) -- Ocugen, Inc. ( Ocugen or the Company ) OCGN, a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S.